Statera Biopharma, Inc.
STAB
$0.00
$0.000.00%
OTC PK
| 09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | 09/30/2021 | |
|---|---|---|---|---|---|
| Revenue | 1.44M | 1.01M | 236.50K | 236.50K | 236.50K |
| Total Other Revenue | 997.80K | 997.80K | 997.80K | -- | -- |
| Total Revenue | 3.69M | 3.25M | 2.48M | 1.49M | 236.50K |
| Cost of Revenue | 1.10M | 1.04M | 842.00K | 488.30K | 115.90K |
| Gross Profit | 2.59M | 2.21M | 1.64M | 998.70K | 120.60K |
| SG&A Expenses | 13.82M | 18.33M | 20.03M | 20.11M | 17.66M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.83M | 32.50M | 34.84M | 32.43M | 24.81M |
| Operating Income | -21.15M | -29.24M | -32.36M | -30.94M | -24.57M |
| Income Before Tax | -91.86M | -101.23M | -104.35M | -101.88M | -28.86M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -91.86 | -101.23 | -104.35 | -101.88 | -28.86 |
| Earnings from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 24.90K | 30.20K | 27.00K | 24.30K | 13.40K |
| Net Income | -91.83M | -101.20M | -104.32M | -101.85M | -28.84M |
| EBIT | -21.15M | -29.24M | -32.36M | -30.94M | -24.57M |
| EBITDA | -20.59M | -28.74M | -31.98M | -30.68M | -24.43M |
| EPS Basic | -2.38 | -2.79 | -2.98 | -3.00 | -1.46 |
| Normalized Basic EPS | -0.30 | -0.50 | -0.62 | -0.63 | -0.81 |
| EPS Diluted | -2.38 | -2.79 | -2.98 | -3.00 | -1.46 |
| Normalized Diluted EPS | -0.30 | -0.50 | -0.62 | -0.63 | -0.81 |
| Average Basic Shares Outstanding | 173.27M | 150.07M | 125.13M | 111.29M | 84.49M |
| Average Diluted Shares Outstanding | 173.27M | 150.07M | 125.13M | 111.29M | 84.49M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |